

# Medmarc Casualty Insurance Company ProAssurance Specialty Insurance Company Life Sciences Products and Completed Operations Liability Insurance

A ProAssurance Company

4795 Meadow Wood Lane Suite 335 West Chantilly, VA 20151-2219 Phone: 703-652-1300 Toll free: 1-800-356-6886 Fax: 703-652-1389

Email: apps@medmarc.com

# **New Business Application**

This application is for a Claims Made policy.

- Please answer all questions completely, using attachments if necessary.
- Do not leave any space blank. Please indicate "n/a" if a question is not applicable.
- If there is insufficient space to answer a question, please attach additional pages.
- Please attach current financial information for any privately-held company.

# I. PRODUCTS COMPLETED OPERATIONS

Broker Information		
1. Brokerage name:		
2. License number:		
Please provide a copy of the agency license for the state in whi	h the applicant is located.	
3. Street: C	ty: State: 2	Zip:
4. Broker contact name:		
5. Broker contact email:	6. Broker contact phone:	
7. Billing/finance contact name:		
8. Billing/finance contact email:	9. Billing/finance contact phor	ne:
Applicant/Insured Information		
10. First named insured:		
Please provide the name as it should appear on the policy.		
11. Desired effective date:		
12. Parent company, if applicable:		
13. Date established:		
14. Street: C	ty: State: 2	Zip:
15. Applicant contact name:	Title:	
16. Website:	Phone number	r:
17. First named insured entity structure:		
☐ Individual ☐ Partnership	☐ Corporation	
☐ Joint Venture ☐ Limited Liabili	y Company   Other (please describe)	
18. Additional named insured(s), respective percent of o	wnership, and relationship to you:	
Entity name as it should appear on the policy	% Ownership Relationship	
19. Additional insured(s) and relationship to you:		
Entity name	Relationship	

NBC App. Rev. 01/26/24

20. List companies or assets acquired (A) or so	old (S) wit	hin the last five years.	
Entity	A/S	Date Acquired/Sold	Description
21. Provide a description of your operations a	nd produ	cts.	
22. Do you belong to any industry trade group	os? Check (	all that apply.	
☐ AdvaMed		□ MDMA	☐ Other
If other, please list the organization(s).			
23. Are you accredited by any certifying bodie	s? Check a		_
		☐ MedAccred	□ Other
If other, please list the organization(s).			
<b>Current Insurance Information</b>			
24. Current insurance company:			
25. Current type of insurance:		☐ Occurrence	☐ Claims Made
26. Policy renewal date:			
27. Current limit of insurance:			
Provide desired limits, if different from current limit	t.		
28. Current self-insured retention or deductib	le:		
Provide desired self-insured retention or deductible	, if differer	nt from current.	
29. Current retroactive date (if claims made):			
If more than one, please attach current schedule of			
30. Does your firm currently carry excess liabi	•	•	
If yes, please provide the coverage information req	uested belo		Claims Made
Carrier Limit		Coverage	Retro Date
31. May we provide you with quotes for other	r lines of s	2010222	
Excess Liability	r imes or c	•	andard Lines*
*If you are interested in standard lines of coverage	(CGL Auto		
partner, Pharmacists Mutual, please submit an ACC			n, ombrend, avanable imough our
		• •	
Projected Revenue Information	,	LC (Consider response (C)	Foreign revenue (¢)
Duranista was disabbasis a manafastania		J.S./Canada revenue (\$)	Foreign revenue (\$)
Proprietary medical device manufacturing			
Proprietary pharmaceutical/biologic manufact	uring		
Contract manufacturing			-
Contract services for others (e.g., packaging,			
repackaging, sterilization, regulatory)			
Specification development			
Distribution			
Importing for distribution			

NBC App. Rev. 01/26/24 Page **2** of **15** 

		U.S./Canada revenu	e (\$)	Foreign revenue	(\$)
Equipment rental					
Installation/mainter	nance/repair/servicing				
Research and develo	opment				
Consulting/design se	ervices				
Other					
If other, please describ	ле.				
Revenue in the prev	ious three years:				
Year	U.S./Canada revenue (\$)	Foreign revenue (\$)		Total (\$)	
					_
Product Information	n				
32. Do you have pro	oducts under development or in cl	inical testing that yοι	ı expect to int	roduce during the	policy term?
	] Yes	□ No			
If yes, please describe.					
33. Have any produ	cts been discontinued in the last the	hree years?			
	Yes	□ No			
	ntinued products and the reason(s) fo	r discontinuation.			
Product			Reason		
24 Daylay magnifes		دادها دادها ماه سماد			
	cture products for others to sell un ]Yes	lder their labeis? □ No			
	ducts manufactured by others und				
	Yes	□ No			
	ontract manufacturers referenced		plicable, and v	whether you requi	re certificates
of insurance fro		•			
Contract Manufactu	ırer		Certificate o	f Insurance	
			□ Ye	es	□ No
			□ Ye	es	□ No
			□ Ye	es	□ No
•	oducts which are components of o	others' finished produ	ucts?		
	Yes	□ No			
•	products or components from fore				
	Yes	□ No			
If yes, please list the fo	preign countries.				
					_

NBC App. Rev. 01/26/24 Page **3** of **15** 

39. Are any of y	our pro	oducts specifically exclu	ided from your cu	rrent coverag	e?	
	☐ Yes			o		
If yes, please list t	the exclu	ıded products.				
40. Do any of yo	our pro	ducts include embedde	ed software?			
	☐ Yes		□ No	0		
41. Do your pro	ducts h	nave internet connectiv	ity?			
	☐ Yes		□ No	0		
42. Do you com	•					
	☐ Yes		□ No			
		g physician have an ow	nership stake in y	our company,	or otherwise benef	fit financially from the
sale or use of		duct you are selling?				
44.5	☐ Yes		□ No	)		
44. Do you perf			□ N	_		
45. D	☐ Yes		□ No			
45. Do your pro	oducts o	consist of or contain any	·	-	-based products?	
	□ Yes		□ No	)		
Regulatory Hist	ory					
46. Is your facili	ity regi:	stered with FDA?	☐ Yes		□ No	□ N/A
If yes, h	ow are	you designated?	☐ Manufactur	er		
			☐ Contract ma	anufacturer		
			☐ Specificatio	n developer		
			☐ Packager/re	packager		
			☐ Contract ste	erilizer		
			☐ Initial impo	rter		
1		as your last FDA	Date:			
inspecti	on?					
			If you have received copies of the 483			five years, please attach
47 Have any of	· vour n	roducts been removed		· · · · · · · · · · · · · · · · · · ·	·	)
47. Have ally Of	☐ Yes				the past two years:	
If yes, please com				,		
1	Class	Product		Reason		Closed?
Necan Bate	Crass	Troduct		- Nedson		☐ Yes ☐ No
						☐ Yes ☐ No
						☐ Yes ☐ No
48. Do you have	e a writ	ten procedure for initia	ating and conduct	ing product re	rcalls?	
lo. Do you nave	☐ Yes					
49. Have you re		an FDA Warning Letter				
	☐ Yes		□ No			
If ves. please atta		es of the Warning Letter a				
		ed a GMP or similar self			ned for you by a thi	ird party, in the last 12
months?				•	•	•
	☐ Yes			)		
If yes, please prov	vide a co	ppy of the audit report.				

NBC App. Rev. 01/26/24 Page **4** of **15** 

51. Do you advertise your product directly to consumers/pa	tients?
□ Yes □	No
If yes, please indicate in which media formats you advertise.	
☐ Television/radio ☐	Social media (Facebook, Instagram, sponsored posts, etc.)
□ Internet □	Print media (newspapers, magazines, etc.)
☐ Direct mail ☐	Other
52. Do any of your products require a "black box warning," F	REMS, or other significant safety warning?
☐ Yes ☐	No
If yes, please attach copies of the "black box warning," REMS mate	
53. In the past two years, have you reported or issued any o	f the following? <i>Check all that apply.</i>
☐ MDRs or adverse event reports ☐ Public health no	otification or Dear Doctor/Healthcare
field/safety ale	•
54. In the past two years, have you had any Serious Adverse	
☐ Yes ☐	
If yes, please attach descriptions of the unreported SAEs.	
Human Clinical Trial History	
55. Are you using a contract research organization (CRO) in a	any of your studies?
	No
56. Do you use HHS-registered institutional review boards	If no, please explain.
(IRBs)?	
☐ Yes ☐ No	
57. Do you use indemnification agreements with	If no, please explain.
investigators, IRBs, and CROs?	
☐ Yes ☐ No	
58. Have any of your IRBs, investigators, or clinical sites	If yes, please explain.
received a Warning Letter or been the subject of an	
adverse FDA action?	
☐ Yes ☐ No	
59. Have you or your investigator ever been cited,	If yes, please explain.
debarred, fined, or suspended?	
☐ Yes ☐ No	If you make a symbolic
60. Have any trials been discontinued or suspended for	If yes, please explain.
safety reasons, whether by you, FDA, or another authority?	
	If yes, please explain.
61. Have any subjects had a serious adverse event (life-	i ij yes, piease explain.
threatening, death, hospitalization, disability or permanent damage, congenital anomaly or birth	
defect, or required intervention to prevent one of	
these outcomes)?	
☐ Yes ☐ No	
□ 1€3 □ INU	

- (a) is life threatening;
- (b) is death;
- (c) required hospitalization (initial or prolonged);
- (d) is disability or permanent damage;
- (e) is a congenital anomaly or birth defect;
- (f) required intervention to prevent permanent impairment or damage; or
- (g) required medical intervention to prevent one of the outcomes (a) through (f) above.

NBC App. Rev. 01/26/24 Page **5** of **15** 

<sup>&</sup>lt;sup>1</sup> **Serious Adverse Event** means an undesirable experience associated with your product where the outcome to the patient:

62. Do any of your trials involve subjects who are	If yes, please explain.
members of a "vulnerable" patient population?	
☐ Yes ☐ No	
63. Are you planning any foreign clinical trials during the	If yes, please explain.
policy term?	
☐ Yes ☐ No	
64. Are you sponsoring any clinical trials in which you have	If yes, please explain.
invited your own employees to participate?	
☐ Yes ☐ No	
65. Are any investigator-sponsored trials using your	If yes, please explain.
product?	
☐ Yes ☐ No	
66. Are any of your investigational (i.e., unapproved) drugs	If yes, please explain.
or devices accessible to seriously ill test subjects who	
are not candidates for clinical trials?	
☐ Yes ☐ No	
67. Do you export drugs for patients in foreign markets	If yes, please explain.
before those drugs have received marketing approval	
in the U.S.?	
☐ Yes ☐ No	
Human Clinical Trial Sponsorship and Funding	
68. Is the named insured the trial sponsor?	
	No
If no, please explain.	
69. How are your clinical trials funded?	
Source	Amount
Source	AIIIOUIIL

# Continue to the next page.

NBC App. Rev. 01/26/24 Page **6** of **15** 

<sup>&</sup>lt;sup>2</sup> "Vulnerable" patients include children, prisoners, pregnant women, handicapped or mentally-disabled persons, or economically or educationally-disadvantaged persons, as defined by 21 CFR 56.111(3).

70. Please  Protocol: Number & Name	Type of Trial <sup>3</sup>	Risk Level <sup>4</sup>	Product Name & Description	Trial Phase	Total Subjects Projected	Sub Enrollm Policy Past 12 Next 1.	ject ent for Term	Trial	Date	FDA Classification for Trial Status <sup>5</sup>	Number of Trial Sites	Trial Locations
		□ SR										□ Foreign
		□ NSR										☐ Domestic
		☐ Drug										□ Both
		□ SR										☐ Foreign
		□ NSR										☐ Domestic
		☐ Drug										☐ Both
		□ SR										☐ Foreign
		□ NSR										☐ Domestic
		☐ Drug										□ Both
If Foreign Tr	ial Locations	is checked pl	lease list countries where	they resid	le:							
Please list a	ny additional	clinical trials	s on a separate page and	include as	s an attachme	nt.	<del></del>				<u> </u>	

# <sup>3</sup> Type of Trial

**Human Clinical Trial Log** 

- Treatment trial tests experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy
- Prevention trial looks for better ways to prevent disease in people who have never had the disease, or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes.
- Diagnostic trial conducted to find better tests or procedures for diagnosing a particular disease or condition
- Screening trial tests the best way to detect certain diseases or health conditions
- Quality of Life trial (or Supportive Care trials) explores ways to improve comfort and the quality of life for individuals with a chronic illness
- Registry trial observational studies in which the events that happen to test subjects with a specific disease or condition are recorded without pre-defined treatment

- Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;
- Is purported or represented to be for use supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;
- Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or
- Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

All other devices are considered to be of Nonsignificant Risk (NSR).

- Pending not yet recruiting
- Ongoing recruiting and enrollment completed; study proceeding according to or ahead of schedule
- Delayed study behind schedule
- Withdrawn study halted prematurely prior to enrollment of the first participant
- Suspended recruiting or enrolling participants has halted prematurely but potentially will resume
- Terminated study halted prematurely and will not resume; participants are no longer being examined or treated
- Completed study has concluded normally; participants are no longer being examined or treated

NBC App. Rev. 01/26/24 Page **7** of **15** 

<sup>&</sup>lt;sup>4</sup> FDA defines a Significant Risk **(SR)** Device as a device that:

<sup>&</sup>lt;sup>5</sup> FDA classifications for trial status:

Claim/Incident I	nformation			
71. Has any insu	irance company cancelle  Ves	d or refused to renew	•	
If yes, please explo				
ij yes, piedse expit	am.			
72. Please attac	h copies of previous carr	iers' loss runs for a mi	nimum of the last five year	s. If loss runs are not available
at this time,	you may complete the c	hart below and supply	the loss runs prior to bindi	ing coverage.
Policy Period	Carrier	# of Claims	s \$ Amount Paid	\$ Amount in Reserves
, , , ,				
Check here if you	have not previously purchas	sed products liability cov	erage. $\square$	·
II. OPTIONA	L COVERAGE: IVIAN	JFACTURERS' ERR	ORS AND OMISSIONS	ı
		s and Omissions coverag	e, please complete this section	n. If this coverage is not desired,
skip to page 13 to complete the application.				
<b>Current Errors 8</b>	& Omissions Insurance In	formation		
74. Current insu	rance company:			
75. Current type	· · · · · · · · · · · · · · · · · · ·	☐ Occurrence		Claims Made
76. Policy renew	val date:			
77. Current limit	t of insurance:			
Provide desired lin	nits, if different from currer	nt limit.		
78. Current self-	insured retention or ded	luctible:		
Provide desired se	lf-insured retention or dedu	ıctible, if different from o	current.	
79. Current retr	oactive date (if claims ma	ade):		
If more than one,	please attach current sched	lule of retroactive dates.		

NBC App. Rev. 01/26/24 Page **8** of **15** 

<sup>&</sup>lt;sup>6</sup> Manufacturers' Errors and Omissions is a Claims Made and Reported policy, available on ProAssurance Specialty (non-admitted) only.

Product or Service Information		
80. What is the acceptable downtime for your	☐ No downtime is acce	ptable
product/service according to your average	☐ 1 day or less	
customer's needs?	☐ 2 days or less	
	☐ 3 days or less	
81. What is the worst negative consequence that		
could happen to your customers' operations if		
your products/services were to fail or stop		
working?		
82. Who are your five largest customers?	Size of Contract	Duration of Contract
83. Are your products used in:		·
a. Clinical trials	□ No	
b. Research/laboratory settings ☐ Yes	□ No	
c. Hospitals/medical facilities   Yes	□ No	
. ,	<del>-</del>	
Quality Control, Training, and Support		
	13485	
·	9001	
	Mark	
	derwriters Laboratory (UI	)
	ner:	<del>-</del> 7
85. Do you have a records retention policy for the pro	ducts vou manufacture. s	ell. or service?
□ Yes □	•	,
86. Do you have a documented training plan for empl	ovees. contractors. distrib	utors, and/or end users of your
products?	, ,	,
☐ Yes ☐	No	□ N/A
87. Do you install, customize, or service your products	?	
☐ Yes ☐		
88. Do others install, customize or service your	□ Vaa □ Na	
products?	☐ Yes ☐ No	
a. If yes, do you provide formal training?	☐ Yes ☐ No	
b. Written instructions?	☐ Yes ☐ No	
c. Sign off on the final product?	☐ Yes ☐ No	
d. Require liability insurance for those	☐ Yes ☐ No	
installing or servicing your products?		
89. Do you have contingency plans to service a custon	ner who experiences a crit	ical failure of your product or service?
□ Yes □	No	
If yes, please provide a copy of the contingency plan.		
90. Do you provide service and repair of products oth	er than your own?	
□ Yes □	No	
a liftyes what percentage of total service rev	vanue ganarated by this w	vork?


NBC App. Rev. 01/26/24 Page **9** of **15** 

Suppliers			
91. What percentage of your component		Please list vendors:	
parts are supplied by outside vendors?			
92. What percentage of your component		Please list countries:	
parts are supplied by foreign-based			
companies?			
93. Do you ever agree to hold harmless any suppl	liers for claims a	arising out of their products?	
☐ Yes	□ No		
If yes, please explain.			
94. Do you require Certificates of Insurance from	your suppliers?	?	
☐ Yes	□ No		
If yes, what limits of liability do you require?		Amount: \$	
Contracts			
95. Does your legal counsel review and approve all	contracts, adv	ertising, and promotional mate	erials and brochures?
☐ Yes	□ No		
96. Do you require your customers to sign written	agreements tha	at outline the specification of p	products and services you
will provide?			
☐ Yes	□ No		
If yes, please provide a sample contract.			
97. Do all of your contracts include the following c	lauses?		
a. Force majeure		☐ Yes	□ No
b. Disclaimer of warranties		☐ Yes	□ No
c. Limitation of liabilities		☐ Yes	□ No
i. If yes, in what amount?		\$	-
d. Exclusion for consequential damages		☐ Yes	 □ No
e. Customer acceptance of interim chang	es and	☐ Yes	□ No
final product			
f. Hold harmless provision		☐ Yes	□ No
g. Indemnification clause		☐ Yes	□ No
h. Payment terms		☐ Yes	□ No
Historical Information			
If you answer "Yes" to any of the questions in this	section, please	e list all occurrences and includ	e the following
information: (1) date of incident; (2) description of			_
settlement/judgment and the amount. Please atta	ch additional she	eets if more space is needed.	
98. Have any of your customers had a financial loss	s If ves.	olease describe.	
because of a problem related to your product of			
service?			
☐ Yes ☐ No			
99. Have you had any repeated verbal or written	If yes,	please describe.	
complaints from your customers that were not	" "		
easily remedied?			
☐ Yes ☐ No			

NBC App. Rev. 01/26/24 Page **10** of **15** 

100. Have there been any problems with below			• • • •	ase describe.	
	•	nance of your products o			
		or not a complaint was			
	Yes	□ No			
1		ustomer stop payment o	• • • • •	ase describe:	
request a	ı refund	because of a product or	service		
problem	in the la	st three years?			
	Yes	□ No			
102. Have you	ı had a c	ustomer bring suit or th	reaten If yes, ple	ase describe:	
to bring	suit beca	use of a problem with y	our		
product	or servic	e?			
Y	'es	□ No			
Product Reca					
				ed from the market in the pa	st three years because of a
problem		vith a product or service			
	☐ Yes		☐ No		
If yes, please spe	cify the fo	ollowing below:			
Recall Date	Class	Product	R	eason	Closed?
					☐ Yes ☐ No
					☐ Yes ☐ No
Please describe	: financial	settlements or other reme	ediation associated with	the recall/removal, if any.	
Claim/Incider	it Inform	nation			
104. Has any	insuran	ce company cancelled o	r refused to renew yo	ur Manufacturer's Errors and	d Omissions insurance?
	☐ Yes	5	□ No		
If yes, please ex	kplain.				
		•		ors and Omissions loss runs	
1			at this time, you may	complete the chart below a	nd supply loss runs prior
to bind	ling cove	rage.			
Policy Perio	d	Carrier	# of Claims	\$ Amount Paid	\$ Amount
			0, 0.0	<i>ϕ</i>	in Reserves
Check here if vi	ou have n	ot previously purchased M	anufacturers' Errors and	d Omissions coverage 🔲	

NBC App. Rev. 01/26/24 Page **11** of **15** 



Continue to the next page.

NBC App. Rev. 01/26/24 Page **12** of **15** 

# **Insurance Fraud Warnings and Important Notices**

For your protection, the following warning is required by various state laws: any person who knowingly and with the intent to injure, defraud, or deceive any insurance company or other person, files a statement of claim or an application containing any false, incomplete or misleading information is guilty of a crime and may be subject to criminal and civil penalties, which may include imprisonment, fines, and denial of insurance.

# **State Specific Fraud Warning Statements**

#### **ALABAMA**

Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or who knowingly presents false information in an application for insurance is guilty of a crime and may be subject to restitution fines or confinement in prison, or any combination thereof.

# ARKANSAS / DISTRICT OF COLUMBIA / LOUISIANA / RHODE ISLAND / WEST VIRGINIA

Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or knowingly presents false information in an application for insurance is guilty of a crime and may be subject to fines and confinement in prison.

# **CALIFORNIA**

For your protection California law requires the following to appear on this form:

Any person who knowingly presents false or fraudulent information to obtain or amend insurance coverage or to make a claim for the payment of a loss is guilty of a crime and may be subject to fines and confinement in state prison.

#### **COLORADO**

It is unlawful to knowingly provide false, incomplete, or misleading facts or information to an insurance company for the purpose of defrauding or attempting to defraud the company. Penalties may include imprisonment, fines, denial of insurance, and civil damages. Any insurance company or agent of an insurance company who knowingly provides false, incomplete, or misleading facts or information to a policyholder or claimant for the purpose of defrauding or attempting to defraud the policyholders or claimant with regard to settlement or award payable from insurance proceeds shall be reported to the Colorado Division of Insurance within the Department of Regulatory Agencies.

## **FLORIDA**

Any person who knowingly and with intent to injure, defraud, or deceive any insurer files a statement of claim containing any false, incomplete, or misleading information is guilty of a felony of the third degree.

# **KENTUCKY**

Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance containing any materially false information or conceals, for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act, which is a crime.

.....

# MAINE / TENNESSEE / VIRGINIA / WASHINGTON

It is a crime to knowingly provide false, incomplete or misleading information to an insurance company for the purpose of defrauding the company. Penalties may include imprisonment, fines, or denial of insurance benefits.

# **MARYLAND**

Any person who knowingly or willfully presents a false or fraudulent claim for payment of a loss or benefit or who knowingly or willingly presents false information in an application for insurance is guilty of a crime and may be subject to fines and confinement in prison.

# **NEW JERSEY**

Any person who includes any false or misleading information on an application for an insurance policy is subject to criminal and civil penalties.

.....

# **NEW MEXICO**

Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or knowingly presents false information in an application for insurance is guilty of a crime and may be subject to civil fines and criminal penalties.

NBC App. Rev. 01/26/24 Page **13** of **15** 

## **NEW YORK**

# **Fraud Warning**

Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance or statement of claim containing any materially false information, or conceals for the purpose of misleading, information concerning any fact material thereto, commits a fraudulent insurance act, which is a crime and shall also be subject to a civil penalty not to exceed five thousand dollars and the stated value of the claim for each such violation.

# **IMPORTANT NOTICE**

In the event you are applying for claims-made coverage, please note the following important information. The information provides you with important guidance in the event your purchase claims-made coverage from us.

- 1. This is a claims-made policy.
- 2. This policy is subject to its terms and conditions:
  - a. applies only to any claim first made against the insured during the policy period or any applicable Extended Reporting Period; and
  - b. does not apply to any claim first made against the insured after the policy period or any applicable Extended Reporting Period or reported after coverage termination.
- 3. This policy provides no coverage for claims arising out of Occurrences which took place prior to any Retroactive Date shown in the policy.
- 4. During the first several years of a claims-made relationship, claims made rates are comparatively lower than occurrence rates. The insured can expect substantial annual premium increases, independent of overall rate level increases, until the claims made relationship reaches maturity.
- 5. All coverage for the policy ceases upon the policy termination date, except for the sixty (60) day automatic Basic Extended Reporting Period, unless an additional Supplemental Extended Reporting Period is purchased.
- 6. A Supplemental Extended Reporting Period of five (5) years is available for purchase upon the payment of additional premium. Potential coverage gaps may arise upon expiration of the Extended Reporting Period. Within thirty (30) days after policy termination, we will send you written notice describing the Basic Extended Reporting Period, the availability of, and the premium for, and the importance of purchasing additional Extended Reporting Period coverage. You must send us a written notice requesting the Supplemental Extended Reporting Period endorsement within the greater time period of ninety (90) days after termination of coverage or thirty (30) days from our mailing or delivery date of the notice for the Supplemental Extended reporting Period.
- 7. The rates for the Supplemental Extended Reporting Period will be based upon the rates in effect at the time of coverage termination. Such rates may be subject to substantial increase over the rates currently in effect and such rates may or may not be indicative of future rate changes. Upon your written request, we will provide you with the average statewide percentage changes and the effective date of each rate revision for this particular type of insurance which we have implemented in the state of New York during the five-year period immediately preceding the effective date of the policy.

# ОНЮ

Any person who, with intent to defraud or knowing that he is facilitating a fraud against an insurer, submits an application or files a claim containing a false or deceptive statement is guilty of insurance fraud.

## **OKLAHOMA**

**WARNING:** Any person who knowingly, and with intent to injure, defraud or deceive any insurer, makes any claim for the proceeds of an insurance policy containing any false, incomplete or misleading information is guilty of a felony.

# **OREGON**

Any person who knowingly and with intent to defraud any insurance company or another person files an application for insurance or statement of claim containing any materially false information, or conceals for the purpose of misleading information concerning any fact material thereto, may be committing a fraudulent insurance act, which may be a crime and may subject the person to criminal and civil penalties.

# **PENNSYLVANIA**

Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance or statement of claim containing any materially false information or conceals for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

NBC App. Rev. 01/26/24 Page **14** of **1**5

The undersigned authorized officer of the applicant warrants that the statements set forth in this Application are true and complete, and acknowledges and understands that the Medmarc Casualty Insurance Company and its affiliated company, ProAssurance Specialty Insurance Company, are relying on the accuracy and completeness of such information in determining eligibility, qualification, and pricing for the insurance provided. The undersigned also warrants that it has not suppressed or misstated any material facts or made any misleading representations. If the information provided in this Application should change between thedate of the Application and the effective date of the policy, the undersigned warrants that he or she will immediately report such changes to the Insurer. Completing and signing this Application does not bind the undersigned to purchase this insurance, nor does it bind coverage. Coverage will not be bound, nor will a policy be issued, until the applicant signifies acceptance of the company's premium quotation.

# (For Montana only, the word "warrants" in the paragraph above is replaced with "represents.")

By signing below, you consent to the receipt of electronic notices and documents (collectively, "Documents"). Documents include any notice or document required as part of an insurance transaction or that is to serve as evidence of coverage. Notwithstanding the previous information, you may request at any time to have a Document sent to you in paper form also. You may also withdraw your consent at any time. Upon information and belief, the only software/hardware requirements for you to access a Document are a valid email address and the ability to open Documents in various formats. You can request a paper copy of a Document withdraw your consent, and/or notify us of a problem opening a Document, by contacting our support team at: LSS@medmarc.com.

Authorized Signature:	Date:
Print Name:	
Title:	
Email:	
If you are electronically submitting this document, apply your electronic signature to this form by check Acceptance box below. By doing so, you agree that your use of a key pad, mouse, or other device to check Acceptance box constitutes your signature, acceptance, and agreement as if actually signed by you in a and effect as a signature affixed by hand.  Electronic Signature and Acceptance - Authorized Signature	neck the Electronic Signature and

Please return your signed application using one of the following:

Fax: (703) 652-1389

Email or click Submit: apps@medmarc.com

Mailing: 4795 Meadow Wood Lane, Suite 335 West, Chantilly, VA 20151



NBC App. Rev. 01/26/24 Page **15** of 15